Dare Bioscience
DARE
16 hedge funds and large institutions have $519K invested in Dare Bioscience in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 5 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0.09% less ownership
Funds ownership: 0.63% → 0.54% (-0.09%)
11% less funds holding
Funds holding: 18 → 16 (-2)
38% less capital invested
Capital invested by funds: $842K → $519K (-$323K)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$41.4K |
| 2 |
Renaissance Technologies
New York
|
+$17K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$11.3K |
| 4 |
Barclays
London,
United Kingdom
|
+$7.37K |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$6.06K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$104K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$53.8K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$27K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$14.6K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$11K |
DARE Hedge Fund Activity: Q4 2018 in Review
16 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Dare Bioscience (DARE) for Q4 2018, worth a combined $519K — down 38% from $842K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of DARE and 3 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Geode Capital Management, adding an estimated $41.4K. The largest seller was Citadel Advisors, exiting entirely with an estimated $104K sold.
- 16 institutional investors held Dare Bioscience (DARE) as of Q4 2018, down from 18 in Q3 2018.
- Funds reported $519K of Dare Bioscience stock for Q4 2018, down 38% quarter-over-quarter.
- 3 funds opened new Dare Bioscience positions in Q4 2018 and 5 closed out, a net change of -2 holders.
- The largest Dare Bioscience buyer in Q4 2018 was Geode Capital Management, an estimated $41.4K added.
- The largest Dare Bioscience seller in Q4 2018 was Citadel Advisors, an estimated $104K sold.
Based on aggregated 13F filings for Q4 2018.